A biological classification for Alzheimer's disease - Amyloid, Tau and Neurodegeneration (A/T/N): Results from the Argentine-Alzheimer's Disease Neuroimaging Initiative

Abstract

Objective: To describe the Amyloid, Tau, Neurodegeneration (A/T/N) research framework classification in the Argentine-Alzheimer Neuroimaging Initiative (ADNI) cohort. Methods: 23 Mild Cognitive Impairment (MCI), 12 Alzheimer?s Disease (AD) and 14 controls were studied with the ADNI-2 protocol. Patients were categorized according to ?A? Aβ biomarkers, ?T? tau biomarker, and ?N? neurodegeneration. Results: A+/T+/N+ at baseline was found in 2/14 controls (14%), 2/10 early MCI (20%), 6/13 late MCI (46%) and 11/12 mild dementia (91%). Suspected non- AD pathophysiology (SNAP, A-/T-/N+) was found in 1/14 controls (7%), 2/10 early MCI (20%), 2/13 late MCI (15%) and 1/12 mild dementia (8%). MCI with A+/T+/N+ showed 75% (6/8) and A-/T-/N+ 50% (2/4) of conversion to dementia in two years.Conclusions: This is the first report from this region based on AD biomarkers and the new A/T/N classification. Our findings suggest that this biological classification is better for prognosis in a short time than the classical clinical one.